ALSA Ventures
Overview
ALSA Ventures is a London-based venture capital firm that invests in early-stage life science companies, focusing on novel therapeutics from the discovery stage to early clinical development.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Promatix Biosciences | Mar 2021 | Seed | Lead |
| Vantage Biosciences | Jul 2023 | Seed | Lead |
| Jatri | Apr 2023 | Series A | Co-investor |
| ReproNovo | May 2025 | Series A | Co-investor |
| Epsilogen | Sep 2024 | Series B Extension | Co-investor |
For institutional investors. Book with your work email.
Key People
Bruce Goldsmith
Venture Partner
Katie Sunnucks
Investment Director
Julia Jones
Investment Manager
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is ALSA Ventures based?
ALSA Ventures is headquartered in London, United Kingdom.
When was ALSA Ventures founded?
ALSA Ventures was founded in 2019.
How many portfolio companies does ALSA Ventures have?
ALSA Ventures has 6 portfolio companies in Caplight's dataset.
What are some companies in ALSA Ventures's portfolio?
Portfolio companies visible on Caplight include Promatix Biosciences, Vantage Biosciences, Jatri, ReproNovo, Epsilogen.
What was ALSA Ventures's most recent investment shown here?
ALSA Ventures's most recent investment in this portfolio sample was in ReproNovo in 2025.
What sectors does ALSA Ventures focus on?
ALSA Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Mobility, Transportation & Logistics, Enterprise Software.
What company stages does ALSA Ventures focus on?
ALSA Ventures typically invests at the Early stage.
What is ALSA Ventures's AUM?
ALSA Ventures's assets under management are estimated between $59.0M and $150.0M.